2022
DOI: 10.1016/j.biopha.2022.113112
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological properties of indirubin and its derivatives

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
10
0
2

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 44 publications
(12 citation statements)
references
References 120 publications
0
10
0
2
Order By: Relevance
“…By the 1970s, IN gained attention for its therapeutic potential in treating various cancers, leading to the introduction of indirubin as a novel treatment for leukemia in China [ 21 ]. Several compounds, including indigo, indirubin, tryptanthrin, among others, are believed to contribute to the medicinal properties of IN [ 21 , 24 , 25 ]. Regarding the mechanism of action, indirubin and its derivatives target STAT5 and CDKs, leading to G1 or G2/M arrest [ 26 29 ].…”
Section: Discussionmentioning
confidence: 99%
“…By the 1970s, IN gained attention for its therapeutic potential in treating various cancers, leading to the introduction of indirubin as a novel treatment for leukemia in China [ 21 ]. Several compounds, including indigo, indirubin, tryptanthrin, among others, are believed to contribute to the medicinal properties of IN [ 21 , 24 , 25 ]. Regarding the mechanism of action, indirubin and its derivatives target STAT5 and CDKs, leading to G1 or G2/M arrest [ 26 29 ].…”
Section: Discussionmentioning
confidence: 99%
“…Indirubin is also a component of the Chinese remedy Danggui Longhui Wan and the main active constituent of a prescription that is responsible for the treatment of chronic myelogenous leukemia (CML) . Indirubin and its derivatives also possess excellent antitumor, anti-inflammatory, and neuroprotective effects , and are effective and selective inhibitors of cyclin-dependent kinases (CDKs), a crucial family of serine–threonine kinases involved in the progression of various tumors . Recently, He’s group designed a new series of CDK–histone deacetylase (HDAC) dual inhibitors based on indirubin that display remarkable suppressive effects against CDK and HDAC …”
Section: Np-inspired Targeted Protein Degradersmentioning
confidence: 99%
“…Furthermore, 6BIO has been investigated for its capacity to activate the Wnt/β-catenin signaling pathway, a crucial player in embryonic development and tissue regeneration [9]. The multifaceted pharmacological activities of 6BIO render it a subject of ongoing research, exploring its potential utility as a pharmacological tool and therapeutic agent across various medical contexts [10].…”
Section: Introductionmentioning
confidence: 99%